Q1: What core technologies do you utilize for circulating tumor DNA profiling? A: We employ highly sensitive and advanced genomic technologies, primarily leveraging ultra-deep Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR). These platforms allow for the precise detection and quantification of ultra-low-frequency mutations from cell-free DNA fragments.

Q2: What are the primary research applications for this liquid biopsy approach? A: This non-invasive method is incredibly valuable across the oncology pipeline. It is widely used for early cancer detection, tracking minimal residual disease (MRD), evaluating therapeutic responses dynamically, and identifying acquired resistance mutations over time.

Q3: Can you customize the gene panels for specific oncology research needs? A: Absolutely. While we offer validated off-the-shelf panels, our expert team specializes in designing bespoke target capture strategies. Through our dedicated ctDNA detection services, we can tailor custom sequencing panels to cover your exact genes of interest and specific actionable mutations.